Home > Publications database > Urinary estrogen metabolites and gastric cancer risk among postmenopausal women. > print

001     177394
005     20240229133739.0
024 7 _ |a 10.1002/cnr2.1574
|2 doi
024 7 _ |a pmid:34766475
|2 pmid
037 _ _ |a DKFZ-2021-02486
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Camargo, M Constanza
|0 0000-0002-1065-2198
|b 0
245 _ _ |a Urinary estrogen metabolites and gastric cancer risk among postmenopausal women.
260 _ _ |a Medford, MA
|c 2022
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1661939155_22790
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Jul;5(7):e1574
520 _ _ |a The overall incidence of gastric cancer in women is half that in men for most global populations. Sex hormone pathways may be involved in carcinogenesis and estrogens have been postulated to protect women against gastric cancer.To evaluate associations of gastric cancer with estrogen metabolites in postmenopausal women.We performed an analysis of 233 gastric cancer cases and 281 age-matched controls from three prospective cohorts and two case-control studies of early-stage gastric cancer, mainly conducted in high-risk Asian populations. Fifteen estrogen-parent (estrone and estradiol) and -metabolite analytes (2-hydroxyestrone, 2-hydroxyestradiol, 2-hydroxyestrone-3-methyl ether, 4-hydroxyestrone; 4-methoxyestrone, 4-methoxyestradiol, 2-methoxyestrone, 2-methoxyestradiol, estriol, 16α-hydroxyestrone, 16-ketoestradiol, 16-epiestriol, and 17-epiestriol) were measured in spot urines using liquid chromatography-tandem mass spectrometry. Odds ratios for association with each marker were estimated by logistic regression. Heterogeneity was assessed by Cochran's Q test. Study-specific odds ratios were pooled by fixed-effects meta-analysis. Urinary levels of estrogen-related molecules were not associated with gastric cancer (adjusted odds ratios ranged from 0.87 to 1.27; p-values >.05), with low between-study heterogeneity (p-values >.1) for all but two metabolites (2-hydroxyestrone-3-methyl ether and 2-methoxyestradiol).To date, this is the first comprehensive assessment of endogenous estrogens with gastric cancer risk in women. Estrogens do not appear to have an etiologic role in gastric cancer risk among postmenopausal women. Given the complex network of sex steroid hormones and their extreme variation over the lifespan, further evaluation of this hypothesis is warranted.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a estradiol
|2 Other
650 _ 7 |a estrogens
|2 Other
650 _ 7 |a estrone
|2 Other
650 _ 7 |a gastric cancer
|2 Other
650 _ 7 |a sex hormones
|2 Other
700 1 _ |a Song, Minkyo
|0 0000-0002-9412-2871
|b 1
700 1 _ |a Xu, Xia
|b 2
700 1 _ |a Zhao, Isaac
|b 3
700 1 _ |a Sampson, Joshua N
|b 4
700 1 _ |a Etemadi, Arash
|b 5
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 6
|u dkfz
700 1 _ |a Lee, Hwi-Won
|b 7
700 1 _ |a Trabert, Britton
|b 8
700 1 _ |a Holleczek, Bernd
|0 P:(DE-He78)53e1a2846c69064e27790dbf349ccaec
|b 9
|u dkfz
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 10
|u dkfz
700 1 _ |a Spaid, Kathleen
|b 11
700 1 _ |a Dawsey, Sanford M
|b 12
700 1 _ |a Lee, Sangjun
|0 0000-0003-4080-0494
|b 13
700 1 _ |a Shimura, Takaya
|b 14
700 1 _ |a Park, Sue K
|b 15
700 1 _ |a Malekzadeh, Reza
|b 16
700 1 _ |a Kang, Daehee
|b 17
700 1 _ |a Rabkin, Charles S
|b 18
773 _ _ |a 10.1002/cnr2.1574
|0 PERI:(DE-600)2920367-3
|n 7
|p e1574
|t Cancer reports
|v 5
|y 2022
|x 2573-8348
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177394
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)53e1a2846c69064e27790dbf349ccaec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2020-09-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-28T13:35:34Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-28T13:35:34Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-05-28T13:35:34Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-15
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-15
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 0
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21